Agios Pharmaceuticals

Agios Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Agios Pharmaceuticals excels in Q4, eyes hematology franchise expansion

Agios Pharmaceuticals showcased strong performance and progress in its Q4 2022 earnings call, emphasizing advancements in its pipeline and commercial capabilities. While facing challenges in estimating sales and patient enrollment progression, the company is well-positioned to capitalize on opportunities for growth and expansion.

Agios Pharmaceuticals reports robust Q1 earnings and strategic growth outlook

Agios Pharmaceuticals demonstrated strong financial performance, progress in PK activation therapies, and strategic decision-making in Q1 2023.
While facing challenges in distribution and inventory management, the company's focus on persistency, clear milestones, and launch dynamics present growth opportunities.
Overall, Agios Pharmaceuticals is well-positioned to capitalize on its strengths, address challenges, and leverage opportunities for future success.

Agios Pharmaceuticals reports strong Q2 performance and eyes growth opportunities

Agios Pharmaceuticals shows strong financial performance and pipeline progress.
Challenges include slow uptake for PYRUKYND and clinical development queries.
Exciting opportunities lie in potential acquisitions, peak sales targets, and upcoming data readouts.

Agios Pharmaceuticals excels in Q3, poised for growth and innovation

Agios Pharmaceuticals delivered a strong performance in Q3 2023, achieving key milestones and reporting solid financial results, positioning the company for future growth.
With a focus on pipeline advancements, commercial success, and financial stability, Agios demonstrates resilience and potential in the competitive pharmaceutical landscape.
While facing challenges in competitive markets and the need for further clarity on certain aspects, Agios has opportunities to capitalize on its strengths and drive innovation and growth.

Agios Pharmaceuticals reports robust earnings and eyes market expansion

Agios Pharmaceuticals showcased strong performance in PK activator development, with positive data readouts and financial stability driving growth prospects.
While facing challenges in market differentiation and regulatory approval, the company's strategic strengths in rare disease treatments and operational efficiency position it for long-term success.
With upcoming launches for thalassemia and sickle cell disease, Agios has opportunities to expand its market presence, drive revenue growth, and establish itself as a key player in rare disease therapeutics.

Agios Pharmaceuticals excels in Q1, eyes strong growth opportunities

Agios Pharmaceuticals showcased strong performance with positive clinical data and solid financials.
While facing challenges in market dynamics and cost management, the company is optimistic about future opportunities.
With a focus on partnerships and revenue growth, Agios aims to deliver value to shareholders.
The company's robust pipeline and cash position position it well for future success.

Agios Pharmaceuticals reports robust Q3 performance and eyes future launches

Agios Pharmaceuticals showcased strong financial performance and progress in key therapeutic areas during their Q3 2024 earnings call. While facing challenges in addressing analyst inquiries and market comparisons, the company remains optimistic about their future prospects. Leveraging their strengths in market engagement and scientific innovation, Agios is well-positioned for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals (AGIO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Agios Pharmaceuticals (AGIO) Moves to Strong Buy: Rationale Behind the Upgrade

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q4 2022 Earnings Conference Call February 23, 2023 8:00 AM ET Company Participants Jessi Rennekamp - Senior Director, Corporate Communications Brian Goff - CEO Sarah Gheuens - CMO & Head, R&D Tsveta Milanova - CCO Cecilia Jones - CFO Conference Call Participants Chris Raymond - Piper Sandler Marc Frahm - Cowen Mary Kate - Bank of America Tessa Romero - J.P. Morgan Greg Renza - RBC Mark Breidenbach - Oppenheimer Danielle Brill - Raymond James Operator Good morning, and welcome to Agios Fourth Quarter and Year-End 2022 Conference Call.

Agios Pharmaceuticals, Inc. (AGIO) Q4 2022 Earnings Call Transcript

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 142.14% and 2.49%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Agios Pharmaceuticals (AGIO) Beats Q4 Earnings Estimates

– Completed Enrollment in Phase 2 RISE UP Study of PYRUKYND ® (mitapivat) in Sickle Cell Disease –

Agios Reports Fourth Quarter and Full Year 2022 Financial Results

Here is how Agios Pharmaceuticals (AGIO) and Alaunos (TCRT) have performed compared to their sector so far this year.

Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year?

CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, February 23, 2023, at 8:00 a.m. ET to report its fourth quarter and year end 2022 financial results and other business highlights.

Agios to Webcast Conference Call of Fourth Quarter and Year End 2022 Financial Results on Feb. 23, 2023

– Consistent and compelling clinical data across rare hematological diseases support five ongoing pivotal trials in thalassemia, sickle cell disease and pediatric pyruvate kinase (PK) deficiency –

Agios Unveils 2023-2026 Value-driving Catalysts Enabling Company's Vision to Transform Patient Outcomes in Rare Diseases

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the grant of inducement equity awards outside of the Company's 2013 Stock Incentive Plan to its newly appointed Chief Commercial Officer, Tsveta Milanova. The grants were approved by the Board of Directors effective as of January 3, 2023 as inducements material to Ms. Milanova entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer

Atara Biotherapeutics

Beam Therapeutics

The attraction of all three biotech stocks is their potential.

3 Under-the-Radar Biotech Stocks to Buy in 2022

CAMBRIDGE, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 7:30 a.m. PT.

Agios to Present at 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023

– Data Suggest Long-term Treatment with PYRUKYND ® in Adults with PK Deficiency is Associated with Improvements in Hemoglobin, Iron Overload, Transfusion Burden and Patient-reported Outcomes, Regardless of Transfusion Status –

Agios Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition

– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND ®  in Adults with Non-transfusion-dependent and Transfusion-dependent α- or β-Thalassemia, Respectively –

Agios Presents Updated PYRUKYND® (mitapivat) Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis and Ineffective Erythropoiesis in Non-transfusion-dependent α- and β-Thalassemia at 64th ASH Annual Meet

CAMBRIDGE, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the appointment of Tsveta Milanova to the role of chief commercial officer, effective Jan. 3, 2023. Ms. Milanova will succeed Richa Poddar, who has been with Agios since 2016 and will continue to serve as the company's chief commercial officer until the end of the year.

Agios Appoints Tsveta Milanova as Chief Commercial Officer

CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the Bank of America 2022 Virtual Biotech SMID Cap Conference on Wednesday, December 7, 2022, at 11:25 a.m. ET.

Agios to Participate in December Investor Conference

First and Only Disease-modifying Therapy for EU Patients with Rare Blood Disorder First and Only Disease-modifying Therapy for EU Patients with Rare Blood Disorder

PYRUKYND® (mitapivat) Approved in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

Agios Pharmaceuticals (AGIO) posts narrower-than-expected Q3 loss while sales miss estimates. The company is enrolling participants across five pivotal studies evaluating the lead drug Pyrukynd.

Agios (AGIO) Q3 Loss Narrower Than Expected, Sales Miss

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Holly Manning - Investor Relations Brian Goff - Chief Executive Officer Sarah Gheuens - Chief Medical Officer and Head, Research and Development Richa Poddar - Chief Commercial Officer Cecilia Jones - Chief Financial Officer Conference Call Participants Marc Frahm - Cowen Mark Breidenbach - Oppenheimer Andy Berens - SVB Andrea Tan - Goldman Sachs Danielle Brill - Raymond James Operator Good day and thank you for standing by and welcome to Q3 2022 Agios Pharmaceuticals, Inc. Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

Agios Pharmaceuticals, Inc. (AGIO) Q3 2022 Earnings Call Transcript

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 14.86% and 29.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Lags Revenue Estimates

– U.S. PYRUKYND ® (mitapivat) Launch Provides Capability Building Platform to Support Expected Future Product Growth and Expansion; Net Revenue of $3.5 Million in Q3 –

Agios Reports Business Highlights and Third Quarter 2022 Financial Results

Sagard Healthcare Partners Acquires Rights to Agios' 5% Royalty on TIBSOVO® U.S. Net Sales Sagard Healthcare Partners Acquires Rights to Agios' 5% Royalty on TIBSOVO® U.S. Net Sales

Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined diseases, today announced the company will host a conference call and live webcast on Thursday, November 3, 2022, at 8:00 a.m. ET to report its third quarter 2022 financial results and other business highlights.

Agios to Webcast Conference Call of Third Quarter 2022 Financial Results on November 3, 2022

CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined diseases, today announced the grant of inducement equity awards outside of the Company's 2013 Stock Incentive Plan to its newly appointed Chief Financial Officer, Cecilia Jones. The grants were approved by the Board of Directors effective as of September 26, 2022 as inducements material to Ms. Jones entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

– Agios Expects a Decision on the Marketing Authorization Application by the European Commission within 67 Days of the Adoption of the Positive CHMP Opinion – – Agios Expects a Decision on the Marketing Authorization Application by the European Commission within 67 Days of the Adoption of the Positive CHMP Opinion –

Agios Receives Positive CHMP Opinion for PYRUKYND® (mitapivat) for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

CAMBRIDGE, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined diseases, today announced that the company is scheduled to present at the following September investor conferences:

Agios to Participate in September Investor Conferences

– In Adults with Pyruvate Kinase (PK) Deficiency Who Are Regularly Transfused, PYRUKYND ® Demonstrated a Statistically Significant and Clinically Meaningful Reduction in Transfusion Burden –

Agios Announces Publication of Phase 3 ACTIVATE-T Data in The Lancet Haematology Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency

News for Agios Pharmaceuticals Stock (AGIO)